IL-18 R beta/IL-1 R7/ACPL Antibodies

210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND₅₀ is typically 0.3-1.0 µg/mL." class="big_lightbox"> 210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND₅₀ is typically 0.3-1.0 µg/mL." alt="In the presence of Recombinant Human TNF-alpha (20 ng/mL, Catalog # 210-TA), Recombinant Human IL-18/ IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (left-hand graph), as measured by the Human IFN-gamma Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/ IL-1F4 (40 ng/mL) is neutralized (right-hand graph) by increasing concentrations of Mouse Anti-Human IL-18 R beta /IL-1 R7 Monoclonal Antibody (Catalog # MAB1181). The ND₅₀ is typically 0.3-1.0 µg/mL." class="big_thumb" />

MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')₂Secondary Antibody (Catalog # F0102B)." class="big_lightbox"> MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')₂Secondary Antibody (Catalog # F0102B)." alt="KG‑1 human acute myelogenous leukemia cell line was stained with Mouse Anti-Human IL‑18 R beta /IL‑1 R7 Monoclonal Antibody (Catalog # MAB118, filled histogram) or isotype control antibody (Catalog # MAB0041, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG F(ab')₂Secondary Antibody (Catalog # F0102B)." class="big_thumb" />

210-TA), Recombinant Human IL-18/IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-y Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/IL-1F4 (40 ng/mL) is neutralized (green line) by increasing concentrations of Human IL-18 R beta /IL-1 R7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF118). The ND₅₀ is typically 0.3-1.2 µg/mL." class="big_lightbox"> 210-TA), Recombinant Human IL-18/IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-y Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/IL-1F4 (40 ng/mL) is neutralized (green line) by increasing concentrations of Human IL-18 R beta /IL-1 R7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF118). The ND₅₀ is typically 0.3-1.2 µg/mL." alt="In the presence of Recombinant Human TNF-a (20 ng/mL, Catalog # 210-TA), Recombinant Human IL-18/IL-1F4 stimulates IFN-gamma secretion in the KG-1 human acute myelogenous leukemia cell line in a dose-dependent manner (orange line), as measured by the Human IFN-y Quantikine ELISA Kit (Catalog # DIF50C). Under these conditions, IFN-gamma secretion elicited by Recombinant Human IL-18/IL-1F4 (40 ng/mL) is neutralized (green line) by increasing concentrations of Human IL-18 R beta /IL-1 R7 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF118). The ND₅₀ is typically 0.3-1.2 µg/mL." class="big_thumb" />